Written by: Tammy McClellan, PharmD
The purpose of this PQI is to expand on therapy management of ibrutinib (Imbruvica®) when used in combination with obinutuzumab (Gazyva®).
Continue reading Ibrutinib (Imbruvica®) Expansion with Obinutuzumab (Gazyva®)
Written By: Jon Suyko, PharmD, BCPS UCHealth Highlands Ranch
Venetoclax (Venclexta®) therapy requires particular parameters be closely followed to ensure optimal patient outcomes. This PQI will review appropriate risk stratification, dosing, and dispensing procedures. These risk stratifications create special challenges for the dispensing of venetoclax. Some medium-risk and all high-risk patients may require hospital admission during titration; communication between the oncology pharmacist, nurse, lab technicians, hematologist, and the patient will ensure the recommended administration guidelines and lab monitoring are followed to ensure patient safety and best outcomes.
Continue reading Venetoclax (Venclexta®) Risk Stratification, Dosing, and Dispensing Procedure
Written by Danny Olszta, PharmD, BCOP Jolliet Oncology Hematology Associates
Chronic Lymphocytic Leukemia (CLL) diagnosis with the chromosomal abnormality of 17p Deletion is associated with a poor prognosis. The 17p deletion is found 3‐10% of the time at diagnosis, but 30‐ 50% at relapse. Testing rates at diagnosis and especially relapse are low. Venetoclax is approved in patients who have relapsed after one therapy and have the 17p deletion. Continue reading CLL and Del17P